NCT05768932 2025-10-15
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
Clinical Trials
12 trialsNCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT06538896 2024-11-26
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06471673 2024-08-26
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
Phase 1/2 Recruiting
NCT06448169 2024-06-07
Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer
Shandong University
Not yet recruiting
NCT04914390 2024-01-22
NeoATCT
Sichuan Provincial People's Hospital
Phase 2 Unknown
NCT04734262 2023-11-18
SPARK
Fudan University
Phase 2 Unknown
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT05861635 2023-05-17
The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4 Unknown
NCT05746728 2023-04-06
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Tongji Hospital
Phase 1/2 Unknown
NCT04501523 2023-02-21
Apollo
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT04913571 2021-06-04
TEMPLATE
Fudan University
Phase 2 Unknown